Warning (512): /home/pharma/website/current/cakephp/app/pharmalicensing/tmp/cache/ is not writable [CORE/cake/libs/cache/file.php, line 267]
Press releases: Health Protection Agency welcomes the Approval of ERWINAZE™ Biologics License Application for Treatment of Acute Lymphoblastic Leukemia
RSS Feeds
Search

Press releases

Stay current with the latest press releases from within the industry.

Health Protection Agency welcomes the Approval of ERWINAZE™ Biologics License Application for Treatment of Acute Lymphoblastic Leukemia

Release issued 18th November 2011

 
  

Salisbury, UK - 18th November 2011 - the Health Protection Agency (HPA) today welcomed the news that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for ERWINAZETM.  The application was made by the HPA's development and commercialisation partner for ErwinazeTM - EUSA Pharma.  ERWINAZETM (asparaginase Erwinia chrysanthemi) is used in the treatment of acute lymphoblastic leukaemia in patients with hypersensitivity to E. coli-derived asparaginase.  ERWINAZETM is currently approved in a number of countries, including Canada, the UK and several European Union member states. 

 

Dr Roger Hinton HPA's Head of Development & Production, commented, "The HPA is extremely pleased with the announcement of the FDA's approval of ERWINAZETM. We have worked diligently to achieve this goal alongside our partners EUSA Pharma, which is key in making this important therapy readily available as rapidly as possible.  Children with acute lymphoblastic leukemia may develop allergy to current asparaginase products and ERWINAZETM provides a key therapeutic alternative for this gravely ill group in several countries around the world. 

 

"The HPA has been producing ERWINASE® for a number of years and it is currently available in many countries around the world, including the UK. This treatment has helped save the lives of thousands of children and today's approval is very positive news for patients in the U.S.

"ERWINAZE® is just one of the biopharmaceutical products produced by HPA at its manufacturing facilities at Porton Down. The agency is responsible for the development and production of a number of products which are produced both in house and in partnership with others.  We will continue to offer this service to allow our expertise to be applied to others in the field of translational development of biopharmaceuticals."

 

About acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most commonly diagnosed childhood cancer.  ALL predominantly affects children and adolescents, with approximately 2,900 patients under the age of 20 diagnosed in the U.S. each year and around 400 in the UK.  ALL treatment is complex, involving a number of stages and many drugs, and includes asparaginase as an essential component of current protocols.  Paediatric treatment is often highly successful, with remission rates of over 95% and 75 - 85% of treated children surviving for at least five years without recurrence of leukemia. 

 

About ERWINAZETM

ERWINAZETM (US Trademark) ERWINASE® (Trademark outside of the US) is an asparaginase enzyme that depletes the level of the amino acid asparagine in the bloodstream.  Asparagine is essential for cell growth, and its removal from the blood inhibits the growth of cells associated with acute lymphoblastic leukemia.  Asparaginase products are derived from bacteria, and approximately 15 - 20 percent of patients develop hypersensitivity to modern products derived from Escherichia coli.  ERWINAZETM, which is produced by Erwinia chrysanthemi, is immunologically distinct from these therapies and is suitable for patients with hypersensitivity to E. coli-derived treatments. 

 

About HPA

The Health Protection Agency is an independent UK organisation that was set up by the government in 2003 to protect the public from threats to their health from infectious diseases and environmental hazards. In April 2013, subject to the usual approvals procedures for establishing new bodies, the Health Protection Agency will become part of a new organisation called Public Health England, an executive agency of the Department of Health. To find out more, visit our website: www.hpa.org.uk or follow us on Twitter @HPAuk.

Company details

If you want to find out more about the company visit Health Protection Agency profile.

Latest Health Protection Agency press releases

(15th September 2008) Funding for Design of New State of the Art Facilities at Health Protection Agency’s Porton Down Site Announced

(17th July 2008) HPA receives Capacity Building Award

(17th July 2008) Health Protection Agency to Design Laboratories for Samples from Mars

(22nd January 2007) Development of a Pan Meningococcal Vaccine for the World

(22nd November 2005) Health Protection Agency and OPi Pharmaceuticals launch drug to help children fight leukaemia

Related reports

Market Research Reports provided by reports.innovaro.com
Health Protection Agency - Company Capsule
Aug 2011 - 8 pages - $75
Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy
Oct 2009 - 199 pages - $15,200
Health Protection Agency - Strategic SWOT Analysis Review
May 2011 - 15 pages - $125
Micromet, Inc. – Product Pipeline Review – H2 2011
Sep 2011 - 80 pages - $500
Company Financials: Micromet
Jan 2010 - $75
ERYtech Pharma - Product Pipeline Review - Q4 2010
Nov 2010 - 36 pages - $500
Talon Therapeutics, Inc. – Product Pipeline Review – Q1 2011
Mar 2011 - 72 pages - $500
Micromet, Inc. – Product Pipeline Review – Q1 2011
Mar 2011 - 81 pages - $500
Mexico: Healthcare System and Drug Regulatory Overview
Jul 2011 - 36 pages - $1,900
The Cancer and Leukemia Group B – Developmental Therapeutics Review – Q4 2010
Nov 2010 - 40 pages - $500
More Related Market Research Reports >>>

More Press Releases

Latest

Frost & Sullivan Award Highlights CIS Pharma’s Technology Innovation in Polymer Industry -- Award Recipient Recognised for its Innovative and Unique Cellophil
Innocoll Provides Update of Regulatory and Partnering Activities for CollaGUARD® Adhesion Barrier and Launches New Product Website
Development of Butyrylcholinesterase-targeted Radiopharmaceuticals for the Treatment of Cancer
19 March 2012 Cerca Insights Opens New Behavioural Pharmacology Laboratory in Penang, Malaysia
Alcon gains exclusive ex-US rights for ocriplasmin, potential first pharmacological treatment for symptomatic vitreomacular adhesion

Most viewed

euroPLX Introduces Tool to Overcome Reject vs. Accept Dilemma in Partnering
Discovery and validation of 13 diabetes biomarkers to be commercialized
Genesis Conference on target to exceed all previous years
Two papers on Neo-Penotran® Forte and Neo-Penotran® Forte-L have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004
TDS® TESTOSTERONE EXCEEDS ANDROGEL® OUTCOMES

Related categories

Therapeutic target
Oncology
Industry sector
Biotechnology
Non-profit org./Government

© Copyright 1998-2012 Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us

(website) 60 queries took 143 ms
NrQueryErrorAffectedNum. rowsTook (ms)
1DESCRIBE `press_release`13131
2DESCRIBE `company`27271
3DESCRIBE `condet`17171
4DESCRIBE `countrycode`441
5DESCRIBE `person`15151
6DESCRIBE `account`29291
7DESCRIBE `product_legacy`661
8DESCRIBE `sales_people`661
9DESCRIBE `profile`14141
10DESCRIBE `currencies`771
11DESCRIBE `update_rec`771
12DESCRIBE `user`24241
13DESCRIBE `enquiry`14141
14DESCRIBE `module_types`661
15DESCRIBE `dms_companies`26261
16DESCRIBE `dms_releases`10101
17DESCRIBE `dms_categories`441
18DESCRIBE `dms_clinical_areas`441
19DESCRIBE `dms_categories_dms_releases`221
20DESCRIBE `dms_clinical_areas_dms_releases`220
21DESCRIBE `dms_releases_sites`551
22DESCRIBE `licopp`23231
23DESCRIBE `development_statuses`551
24DESCRIBE `category`14141
25DESCRIBE `categories_sites`551
26DESCRIBE `categorisation`881
27DESCRIBE `licopps_sites`331
28DESCRIBE `service`15151
29DESCRIBE `story`12121
30DESCRIBE `sites_stories`550
31DESCRIBE `story_assoc`440
32DESCRIBE `companies_sites`330
33DESCRIBE `categories_users`220
34DESCRIBE `authority`330
35DESCRIBE `sites_users`550
36DESCRIBE `press_releases_sites`551
37DESCRIBE `sites`550
38SELECT `Site`.`id`, `Site`.`name`, `Site`.`email_domain`, `Site`.`short_name`, `Site`.`brand` FROM `sites` AS `Site` WHERE `Site`.`id` = 1 LIMIT 1110
39SELECT `Press`.`uid`, `Press`.`slug`, `Press`.`company_id`, `Press`.`created`, `Press`.`lastmod`, `Press`.`issued`, `Press`.`headline`, `Press`.`summary`, `Press`.`body`, `Press`.`is_live`, `Press`.`is_attachment`, `Press`.`user_id`, `Press`.`viewed_counter`, `Company`.`uid`, `Company`.`slug`, `Company`.`name`, `Company`.`condet_id`, `Company`.`person_id`, `Company`.`billing_id`, `Company`.`parent`, `Company`.`has_children`, `Company`.`notes_id`, `Company`.`contact_status`, `Company`.`last_contacted`, `Company`.`profile_id`, `Company`.`account_id`, `Company`.`summary`, `Company`.`is_customer`, `Company`.`change_time`, `Company`.`flags`, `Company`.`is_anon`, `Company`.`is_resource`, `Company`.`satellite`, `Company`.`no_dms`, `Company`.`is_live`, `Company`.`viewed_counter`, `Company`.`created`, `Company`.`last_disabled`, `Company`.`no_trial`, `Company`.`trial_notification_sent`, `User`.`uid`, `User`.`email`, `User`.`name`, `User`.`password`, `User`.`lastlogin`, `User`.`currency`, `User`.`person`, `User`.`customer`, `User`.`operator`, `User`.`company`, `User`.`wantsmail`, `User`.`passwordclue`, `User`.`alias`, `User`.`username`, `User`.`person_id`, `User`.`condet_id`, `User`.`company_id`, `User`.`signup_date`, `User`.`alert_inlic`, `User`.`alert_outlic`, `User`.`alert_company`, `User`.`alert_events`, `User`.`alert_lasttime`, `User`.`stats_access`, `PressSite`.`id`, `PressSite`.`created`, `PressSite`.`modified`, `PressSite`.`press_release_id`, `PressSite`.`site_id` FROM `press_release` AS `Press` LEFT JOIN `company` AS `Company` ON (`Press`.`company_id` = `Company`.`uid`) LEFT JOIN `user` AS `User` ON (`Press`.`user_id` = `User`.`uid`) LEFT JOIN `press_releases_sites` AS `PressSite` ON (`PressSite`.`press_release_id` = `Press`.`uid`) WHERE `PressSite`.`site_id` = 1 AND `Press`.`uid` = '1321896942_4eca8beed70e6' LIMIT 1116
40SELECT `Category`.`uid`, `Category`.`name`, `Category`.`parent`, `Category`.`has_children`, `Category`.`show_children`, `Category`.`show_grandchildren`, `Category`.`members`, `Category`.`num_children`, `Category`.`root`, `Category`.`restricted`, `Category`.`clan`, `Category`.`lft`, `Category`.`rgt`, `Category`.`level`, `Categorisation`.`id`, `Categorisation`.`company_id`, `Categorisation`.`buysell`, `Categorisation`.`category_id`, `Categorisation`.`browse_category_id`, `Categorisation`.`cat_type`, `Categorisation`.`story_id`, `Categorisation`.`network_id` FROM `category` AS `Category` JOIN `categorisation` AS `Categorisation` ON (`Categorisation`.`story_id` = '1321896942_4eca8beed70e6' AND `Categorisation`.`category_id` = `Category`.`uid`) WHERE cat_type="R" ORDER BY `Category`.`root` ASC, `Category`.`clan` ASC, `Category`.`parent` ASC, `Category`.`name` ASC 440
41SELECT `Press`.`uid`, `Press`.`slug`, `Press`.`headline`, `Press`.`body`, `Press`.`issued` FROM `press_release` AS `Press` LEFT JOIN `company` AS `Company` ON (`Press`.`company_id` = `Company`.`uid`) LEFT JOIN `user` AS `User` ON (`Press`.`user_id` = `User`.`uid`) LEFT JOIN `press_releases_sites` AS `PressSite` ON (`PressSite`.`press_release_id` = `Press`.`uid`) WHERE `PressSite`.`site_id` = 1 AND `Press`.`company_id`='275' AND `Press`.`is_live`=1 AND DATE(`Press`.`issued`) <= DATE(now()) AND `Press`.`uid` != "1321896942_4eca8beed70e6" ORDER BY `issued` DESC LIMIT 55531
42SELECT `Category`.`uid`, `Category`.`name`, `Category`.`parent`, `Category`.`has_children`, `Category`.`show_children`, `Category`.`show_grandchildren`, `Category`.`members`, `Category`.`num_children`, `Category`.`root`, `Category`.`restricted`, `Category`.`clan`, `Category`.`lft`, `Category`.`rgt`, `Category`.`level`, `Categorisation`.`id`, `Categorisation`.`company_id`, `Categorisation`.`buysell`, `Categorisation`.`category_id`, `Categorisation`.`browse_category_id`, `Categorisation`.`cat_type`, `Categorisation`.`story_id`, `Categorisation`.`network_id` FROM `category` AS `Category` JOIN `categorisation` AS `Categorisation` ON (`Categorisation`.`story_id` IN ('1222437506_48dcea824ba70', '1216303279_487f50af6f3ff', '1216303379_487f51137726e', '1169461696_45b491c03b7e2', '1133860606_439556ff027e6') AND `Categorisation`.`category_id` = `Category`.`uid`) WHERE cat_type="R" ORDER BY `Category`.`root` ASC, `Category`.`clan` ASC, `Category`.`parent` ASC, `Category`.`name` ASC 000
43 SELECT Press.uid, Press.slug, Press.issued, Press.headline, Press.summary FROM press_release AS Press WHERE Press.is_live = 1 AND Press.issued <= now() GROUP BY Press.uid ORDER BY Press.issued DESC LIMIT 5551
44SELECT `Press`.`uid`, `Press`.`issued`, `Press`.`headline`, `Press`.`slug` FROM `press_release` AS `Press` LEFT JOIN `company` AS `Company` ON (`Press`.`company_id` = `Company`.`uid`) LEFT JOIN `user` AS `User` ON (`Press`.`user_id` = `User`.`uid`) LEFT JOIN `press_releases_sites` AS `PressSite` ON (`PressSite`.`press_release_id` = `Press`.`uid`) WHERE `PressSite`.`site_id` = 1 AND `Press`.`is_live` = 1 AND DATE(`Press`.`issued`) <= DATE(now()) ORDER BY `Press`.`viewed_counter` DESC, `Press`.`issued` DESC LIMIT 55566
45 SELECT Category.uid, Category.parent, Category.root, Category.name, Category.level, Category.lft, CASE Category.root WHEN '560' THEN 0 WHEN '297' THEN 1 ELSE CASE Category.uid WHEN '560' THEN 0 WHEN '297' THEN 1 ELSE NULL END END AS root_order FROM category AS RootCategory LEFT JOIN categorisation AS Categorisation ON Categorisation.category_id=RootCategory.uid AND Categorisation.story_id='1321896942_4eca8beed70e6' AND Categorisation.cat_type='R' LEFT JOIN category AS Category ON (Category.lft <= RootCategory.lft AND Category.rgt >= RootCategory.rgt AND Category.level > 0) WHERE Categorisation.id IS NOT NULL AND RootCategory.root IN (560, 297) GROUP BY Category.uid ORDER BY root_order,lft550
46SELECT `Press`.`uid`, `Press`.`company_id`, `Press`.`viewed_counter` FROM `press_release` AS `Press` LEFT JOIN `company` AS `Company` ON (`Press`.`company_id` = `Company`.`uid`) LEFT JOIN `user` AS `User` ON (`Press`.`user_id` = `User`.`uid`) LEFT JOIN `press_releases_sites` AS `PressSite` ON (`PressSite`.`press_release_id` = `Press`.`uid`) WHERE `PressSite`.`site_id` = 1 AND `Press`.`uid`="1321896942_4eca8beed70e6" AND `Press`.`is_live`>0 LIMIT 1113
47SELECT `Category`.`uid`, `Category`.`name`, `Category`.`parent`, `Category`.`has_children`, `Category`.`show_children`, `Category`.`show_grandchildren`, `Category`.`members`, `Category`.`num_children`, `Category`.`root`, `Category`.`restricted`, `Category`.`clan`, `Category`.`lft`, `Category`.`rgt`, `Category`.`level`, `Categorisation`.`id`, `Categorisation`.`company_id`, `Categorisation`.`buysell`, `Categorisation`.`category_id`, `Categorisation`.`browse_category_id`, `Categorisation`.`cat_type`, `Categorisation`.`story_id`, `Categorisation`.`network_id` FROM `category` AS `Category` JOIN `categorisation` AS `Categorisation` ON (`Categorisation`.`story_id` = '1321896942_4eca8beed70e6' AND `Categorisation`.`category_id` = `Category`.`uid`) WHERE cat_type="R" ORDER BY `Category`.`root` ASC, `Category`.`clan` ASC, `Category`.`parent` ASC, `Category`.`name` ASC 440
48SELECT COUNT(*) AS `count` FROM `press_release` AS `Press` WHERE `Press`.`uid` = '1321896942_4eca8beed70e6' 110
49SELECT COUNT(*) AS `count` FROM `press_release` AS `Press` WHERE `Press`.`uid` = '1321896942_4eca8beed70e6' 110
50UPDATE `press_release` SET `viewed_counter` = 754 WHERE `press_release`.`uid` = '1321896942_4eca8beed70e6'12
51SELECT `Press`.`uid` FROM `press_release` AS `Press` LEFT JOIN `company` AS `Company` ON (`Press`.`company_id` = `Company`.`uid`) LEFT JOIN `user` AS `User` ON (`Press`.`user_id` = `User`.`uid`) LEFT JOIN `press_releases_sites` AS `PressSite` ON (`PressSite`.`press_release_id` = `Press`.`uid`) WHERE `PressSite`.`site_id` = 1 AND `Press`.`uid` = '1321896942_4eca8beed70e6' LIMIT 1113
52SELECT `Category`.`uid`, `Category`.`name`, `Category`.`parent`, `Category`.`has_children`, `Category`.`show_children`, `Category`.`show_grandchildren`, `Category`.`members`, `Category`.`num_children`, `Category`.`root`, `Category`.`restricted`, `Category`.`clan`, `Category`.`lft`, `Category`.`rgt`, `Category`.`level`, `Categorisation`.`id`, `Categorisation`.`company_id`, `Categorisation`.`buysell`, `Categorisation`.`category_id`, `Categorisation`.`browse_category_id`, `Categorisation`.`cat_type`, `Categorisation`.`story_id`, `Categorisation`.`network_id` FROM `category` AS `Category` JOIN `categorisation` AS `Categorisation` ON (`Categorisation`.`story_id` = '1321896942_4eca8beed70e6' AND `Categorisation`.`category_id` = `Category`.`uid`) WHERE cat_type="R" ORDER BY `Category`.`root` ASC, `Category`.`clan` ASC, `Category`.`parent` ASC, `Category`.`name` ASC 440
53SELECT `PressSite`.`id`, `PressSite`.`created`, `PressSite`.`modified`, `PressSite`.`press_release_id`, `PressSite`.`site_id` FROM `press_releases_sites` AS `PressSite` WHERE `site_id` = 1 AND `press_release_id` = '1321896942_4eca8beed70e6' 110
54DESCRIBE `statistics`771
55SELECT `ModuleType`.`id`, `ModuleType`.`handle`, `ModuleType`.`name`, `ModuleType`.`description`, `ModuleType`.`created`, `ModuleType`.`modified` FROM `module_types` AS `ModuleType` WHERE `ModuleType`.`handle` = 'press' LIMIT 1110
56SELECT `Statistic`.`id`, `Statistic`.`module_type_id`, `Statistic`.`company_id`, `Statistic`.`business_object_id`, `Statistic`.`count`, `Statistic`.`hit_date`, `Statistic`.`is_aggregated`, `ModuleType`.`id`, `ModuleType`.`handle`, `ModuleType`.`name`, `ModuleType`.`description`, `ModuleType`.`created`, `ModuleType`.`modified` FROM `statistics` AS `Statistic` LEFT JOIN `module_types` AS `ModuleType` ON (`Statistic`.`module_type_id` = `ModuleType`.`id`) WHERE `business_object_id` = '1321896942_4eca8beed70e6' AND `company_id` = 275 AND `module_type_id` = '9' AND `hit_date` = '2012-05-21' LIMIT 1111
57SELECT COUNT(*) AS `count` FROM `statistics` AS `Statistic` WHERE `Statistic`.`id` = 10691057 110
58SELECT COUNT(*) AS `count` FROM `statistics` AS `Statistic` WHERE `Statistic`.`id` = 10691057 110
59SELECT COUNT(*) AS `count` FROM `statistics` AS `Statistic` WHERE `Statistic`.`id` = 10691057 110
60UPDATE `statistics` SET `id` = 10691057, `module_type_id` = '9', `company_id` = 275, `business_object_id` = '1321896942_4eca8beed70e6', `count` = 2, `hit_date` = '2012-05-21', `is_aggregated` = 0 WHERE `statistics`.`id` = 1069105710
(default) 0 query took ms
NrQueryErrorAffectedNum. rowsTook (ms)
(report) 2 queries took 3 ms
NrQueryErrorAffectedNum. rowsTook (ms)
1DESCRIBE `reports`17171
2SELECT `MarketResearchReport`.`id`, `MarketResearchReport`.`slug`, `MarketResearchReport`.`name`, `MarketResearchReport`.`description`, `MarketResearchReport`.`summary`, `MarketResearchReport`.`content`, `MarketResearchReport`.`isbn`, `MarketResearchReport`.`code`, `MarketResearchReport`.`pages`, `MarketResearchReport`.`published`, `MarketResearchReport`.`net_price_usd`, `MarketResearchReport`.`active`, `MarketResearchReport`.`publisher_id`, `MarketResearchReport`.`views`, `MarketResearchReport`.`tags`, `MarketResearchReport`.`created`, `MarketResearchReport`.`modified` FROM `reports` AS `MarketResearchReport` WHERE `MarketResearchReport`.`active` = 1 AND MATCH (`MarketResearchReport`.`name`, `MarketResearchReport`.`description`, `MarketResearchReport`.`summary`, `MarketResearchReport`.`content`, `MarketResearchReport`.`isbn`, `MarketResearchReport`.`code`) AGAINST ("Health Protection Agency welcomes the Approval of ERWINAZE™ Biologics License Application for Treatment of Acute Lymphoblastic Leukemia") ORDER BY MATCH (`MarketResearchReport`.`name`, `MarketResearchReport`.`description`, `MarketResearchReport`.`summary`, `MarketResearchReport`.`content`, `MarketResearchReport`.`isbn`, `MarketResearchReport`.`code`) AGAINST ("Health Protection Agency welcomes the Approval of ERWINAZE™ Biologics License Application for Treatment of Acute Lymphoblastic Leukemia") DESC , MarketResearchReport.published DESC LIMIT 1010102